Understanding Your Metabolic Blood Panel: A Complete Clinical Guide

A comprehensive metabolic blood panel is the most powerful window into your long-term health trajectory. Yet most patients receive their results with a brief “everything looks normal” — without any explanation of what each value means, how the values relate to one another, or what actions to take. This guide provides a detailed walkthrough of every major metabolic marker, explaining clinical significance, optimal targets, and the interventions that move each parameter in the right direction.

Glucose Metabolism Markers

Fasting Glucose

A 8–12 hour fasted blood glucose reflects primarily hepatic glucose output overnight. Normal is below 5.6 mmol/L (100 mg/dL). Impaired fasting glucose (IFG) is 5.6–6.9 mmol/L; diabetic range is 7.0 mmol/L or above on two occasions.^[1] Limitation: a normal fasting glucose does not rule out post-meal glucose dysregulation or significant insulin resistance (see HOMA-IR below).

HbA1c (Glycated Haemoglobin)

Reflects average blood glucose over 2–3 months. Normal below 5.7% (39 mmol/mol); prediabetes 5.7–6.4%; diabetes 6.5% and above. Treatment target for most patients with T2D: below 7.0%. For remission: below 6.5% without medication for 3+ months.^[2]

Fasting Insulin and HOMA-IR

Fasting insulin is routinely absent from standard blood panels but is arguably the most important early metabolic marker. Reference range for fasting insulin: 2–25 mIU/L, with an optimal level below 8 mIU/L in metabolically healthy individuals.^[3] HOMA-IR (Fasting Insulin × Fasting Glucose ÷ 22.5) above 2.5 indicates significant insulin resistance requiring intervention. We test this in every patient at SehaTalks.

Fructosamine

Fructosamine measures glycated serum proteins, reflecting average glucose over the preceding 2–3 weeks. Useful when HbA1c is unreliable (haemoglobinopathies, haemolysis, iron deficiency). Reference range: 205–285 μmol/L.^[4]

Lipid Markers

Total Cholesterol

Total cholesterol (TC) is the sum of all cholesterol-carrying lipoprotein particles. It is a poor standalone cardiovascular risk predictor — its utility is primarily in calculating other ratios. Desirable TC: below 5.2 mmol/L (200 mg/dL).^[5]

LDL Cholesterol

Low-density lipoprotein cholesterol is the primary pharmacological treatment target. However, LDL-C measures the cholesterol content within LDL particles, not the number of particles. Optimal LDL-C: below 2.6 mmol/L (100 mg/dL) for primary prevention; below 1.8 mmol/L (70 mg/dL) for high-risk patients; below 1.4 mmol/L (55 mg/dL) for very high-risk patients (established ASCVD).^[6]

HDL Cholesterol

HDL-C (high-density lipoprotein cholesterol) is the primary marker of reverse cholesterol transport capacity. Low HDL-C (below 1.0 mmol/L [40 mg/dL] in men, below 1.3 mmol/L [50 mg/dL] in women) is a major cardiovascular risk factor and a strong marker of insulin resistance. Raising HDL through lifestyle: exercise (particularly aerobic) raises HDL by 5–10%; eliminating smoking raises HDL by 10%; reducing refined carbohydrate raises HDL through lowering triglycerides.^[5]

Triglycerides

Fasting triglycerides reflect primarily hepatic VLDL secretion, which is driven by excess carbohydrate intake, insulin resistance, and alcohol. Target: below 1.7 mmol/L (150 mg/dL). Optimal for metabolic health: below 1.1 mmol/L (100 mg/dL). Fasting triglycerides above 2.0 mmol/L (175 mg/dL) indicate significant metabolic dysfunction requiring dietary intervention regardless of LDL-C levels.^[7]

Triglyceride-to-HDL Ratio

As covered in our lipid panel article, this ratio is the most clinically practical screen for small dense LDL predominance and insulin resistance. Optimal: below 1.0 (mmol/L units) or below 2.0 (mg/dL units). Above 1.5 (mmol/L) warrants investigation for insulin resistance.^[8]

Non-HDL Cholesterol

Total Cholesterol minus HDL-C. Captures all atherogenic particles. Target: below 3.4 mmol/L (131 mg/dL) for general population; below 2.6 mmol/L (100 mg/dL) for high-risk patients.^[5]

Apolipoprotein B (ApoB)

One ApoB per atherogenic particle — the most accurate measure of atherogenic particle burden. Target: below 0.9 g/L for primary prevention; below 0.7 g/L for high-risk patients.^[9]

Liver Enzymes

ALT (Alanine Aminotransferase)

ALT is the most specific marker of hepatocellular injury. Elevated ALT indicates hepatic inflammation, most commonly from non-alcoholic fatty liver disease (NAFLD/MASLD) in the metabolic patient. Importantly, the traditional laboratory upper limit of normal (45 U/L in many labs) is too permissive: population studies demonstrate that ALT above 30 U/L in men and 19 U/L in women correlates with significant hepatic steatosis, even within the “normal” range.^[10] We use these stricter thresholds in clinical practice.

AST (Aspartate Aminotransferase)

AST is less specific than ALT but provides additional information. An AST:ALT ratio above 2:1 suggests alcoholic liver disease rather than NAFLD. An AST:ALT ratio below 1 is typical of early NAFLD.^[11]

GGT (Gamma-Glutamyltransferase)

GGT is a sensitive marker of hepatic oxidative stress, bile duct dysfunction, and alcohol intake. Even mildly elevated GGT (above 30 U/L in women, 50 U/L in men) is associated with significantly higher all-cause mortality and cardiovascular risk, independent of alcohol intake.^[12]

Kidney Function

Creatinine and eGFR

Serum creatinine is a byproduct of muscle metabolism, filtered by the glomerulus. eGFR (estimated GFR) is calculated from creatinine, age, sex, and race. CKD is defined as eGFR below 60 for 3+ months, or evidence of structural or functional kidney abnormality. Creatinine is unreliable in low-muscle-mass individuals; cystatin C provides a more accurate eGFR in these cases.^[13]

Urine Albumin-to-Creatinine Ratio (UACR)

The most sensitive early marker of diabetic kidney disease. Should be measured annually in all patients with Type 2 diabetes from the time of diagnosis. Microalbuminuria (UACR 3–30 mg/mmol) is the earliest detectable sign of glomerular injury and is highly reversible with optimal metabolic control and RAS blockade.^[14]

Inflammation and Thyroid

hsCRP (High-Sensitivity C-Reactive Protein)

CRP is the liver’s acute phase reactant, driven by IL-6 from visceral adipose tissue and other inflammatory sources. In the context of metabolic disease, hsCRP is a marker of visceral fat burden and cardiovascular risk. Below 1.0 mg/L: low risk. 1.0–3.0 mg/L: average risk. Above 3.0 mg/L: high risk. The JUPITER trial demonstrated that patients with low LDL but elevated hsCRP achieved significant cardiovascular risk reduction with statin therapy, establishing hsCRP as an independent treatment trigger.^[15]

TSH (Thyroid Stimulating Hormone)

Hypothyroidism raises LDL cholesterol, promotes weight gain, causes fatigue, and impairs metabolic rate — perfectly mimicking metabolic syndrome. TSH should be tested in every patient presenting with dyslipidaemia, unexplained weight gain, or fatigue. Optimal TSH: 0.5–2.5 mIU/L; values above 4.0 mIU/L indicate hypothyroidism in symptomatic patients.^[16]